New developments in pharmacologic management of cerebral ischemia and hemorrhage are reviewed. A number of agents with diverse modes of action have now been shown to be neuroprotective in adult and neonatal animal models when administered either before or after a hypoxic-ischemic insult. As experience improves with these agents in hypoxic-ischemic injury and periventricular-intraventricular hemorrhage in human neonates, there is reason to be optimistic that effective neuroprotective strategies will soon be clinically available. (J Child Neurol 1993;8:7-18) .
Get full access to this article
View all access options for this article.
References
1.
Philip AG, Allan WC, Tito AM, et al: Intraventricular hemorrhage in preterm infants: Declining incidence in the 1980's. Pediatrics1989;84:797-801.
2.
Ford LM, Han BK, Steichen J., et al: Very-low-birth-weight, preterm infants with or without intracranial hemorrhage: Neurologic, cognitive and cranial MRI correlations at 4-8-year follow-up. Clin Pediatr (Phila) 1989;28:302-310.
3.
Hill A., Volpe JJ: Pathogenesis and management of hypoxic-ischemic encephalopathy in the term newborn. Neurol Clin1985;3:31-46.
4.
Volpe JJ: Perinatal hypoxic-ischemic brain injury: Overview, in Fukayama Y, Suzuki Y, Kamoshita S, Casaer P (eds): Fetal and Perinatal Neurology. Basel, Karger, 1992, pp 232-252.
5.
Volpe JJ: Intraventricular hemorrhage in the premature infant—current concepts. Parts I and II. Ann Neurol1989;25:3-11, 109-116.
6.
Flynn CJ, Farooqui AA, Horrocks LA: Ischemia and hypoxia, in Siegel GJ, Agranoff BW, Albers RW , Molinoff PB (eds): Basic Neurochemistry, 4th ed. New York, Raven Press, 1989, pp 783-796.
7.
Vannuci RC: Experimental biology of cerebral hypoxia-ischemia: Relation to perinatal brain damage. Pediatr Res1990;27:317-326.
8.
Vannuci RC: Current and potentially new management strategies for perinatal hypoxic-ischemic encephalopathy. Pediatrics1990;85:961-968.
9.
Volpe JJ: Neurology of the Newborn, 2nd ed. Philadelphia, Saunders, 1987, pp 311-361.
10.
Volpe JJ: Intraventricular hemorrhage in the premature infant—Neuropathology and pathogenesis. Clin Perinatol1989;16:361-386.
11.
Volpe JJ: Intraventricular hemorrhage and brain injury in the premature infant. Diagnosis, prognosis, and prevention. Clin Perinatol1989;16:387-411.
12.
Wigglesworth JS: Current problems in brain pathology in the perinatal period, in Pape KE, Wigglesworth JS (eds): Perinatal Brain Lesions . Cambridge, MA, Blackwell Scientific , 1989, pp 1-24.
13.
Pasternak JF , Groothuis DR, Fischer JM, et al: Regional cerebral blood flow in the newborn beagle pup: The germinal matrix is a "low-flow" structure. Pediatr Res1982;16: 499-503.
14.
DeReuck JL: Cerebral angioarchitecture and perinatal brain lesions in premature and full-term infants. Acta Neurol Scand1984 ;70:391-395.
15.
Hambleton G. , Wigglesworth JS: Origin of intraventricular hemorrhage in the preterm infant. Arch Dis Child1976 ;51:651-659.
16.
Leech RW, Kohnen P.: Subependymal and intraventricular hemorrhages in the newborn. Am J Pathol1974;77:465-476.
17.
Donat JF, Okazaki H., Kleinberg F., Reagan TJ: Intraventricular hemorrhages in full-term and premature infants. Mayo Clin Proc1978;53:437-441.
18.
Donn SM, Roloff DW, Goldstein GW: Prevention of intraventricular hemorrhage in preterm infants by phenobarbitone: A controlled trial. Lancet1981;2:215-217.
19.
De Carolis S., De Carolis MP, Caruso A., et al: Antenatal phenobarbital in preventing intraventricular hemorrhage in premature newborns. Fetal Ther1988;3:224-229.
20.
Wimberly PD , Lou HC, Pedersen H., et al: Hypertensive peaks in the pathogenesis of intraventricular hemorrhage in the newborn. Abolition by phenobarbitone sedation. Acta Paediatr Scand1982;71:537-542.
21.
Porter FL, Marshall RE, Moore JA, Miller RH: Effect of phenobarbital on motor activity and intraventricular hemorrhage in preterm infants with respiratory disease weighing less than 1500 grams . Am J Perinatol1985;2:63-66.
22.
Kuban KC, Leviton A., Krishnamoorthy KS, et al: Neonatal intracranial hemorrhage and phenobarbital. Pediatrics1986;77:443-450.
23.
Bedard MP, Shankaran S., Slovis TL, et al: Effect of prophylactic phenobarbital on intraventricular hemorrhage in high-risk infants. Pediatrics1984;73:435-439.
24.
Hope PL, Stewart AL, Thornburn RJ, et al: Failure of phenobarbitone to prevent intraventricular haemorrhage in small preterm infants. Lancet1982;1:444-445.
25.
Morgan ME, Massey RF, Cooke RW: Does phenobarbitone prevent periventricular hemorrhage in very low-birth-weight babies? A controlled trial. Pediatrics1982 ;70:186-189.
26.
Nelson RM, Leuschen MP, Kasik JW, et al: Effect of phenobarbital on intraventricular hemorrhage in asphyxiated newborn beagles. J Perinatol1985;5:16-20.
27.
Whitelaw A. , Placzek M., Dubowitz L., et al: Phenobarbitone for prevention of periventricular haemorrhage in very low birth-weight infants: A randomized double-blind trial . Lancet1983 ;2:1168-1170.
28.
Shankaran S. , Cepeda EE, Ilagan N., et al: Antenatal phenobarbital for the prevention of neonatal intraventricular hemorrhage. Am J Obstet Gynecol1986;154:53-57.
29.
Morales WJ, Koerten J.: Prevention of intraventricular hemorrhage in very low birth weight infants by maternally administered phenobarbital. Obstet Gynecol1986;68:295-299.
30.
Kaempf JW, Porreco R., Molina R., et al: Antenatal phenobarbital for the prevention of periventricular and intraventricular hemorrhage: A double-blind, randomized, placebo-controlled, multihospital trial. J Pediatr1990;117:933-938.
31.
Kuban KC, Leviton A., Brown ER, et al: Respiratory complications in low-birth-weight infants who received phenobarbital. Am J Dis Child1987;141:996-999.
32.
Goddard-Finegold J., Michael H.: Anti-convulsant concentrations of phenobarbital after cerebrovascular hemodynamics in the newborn dog. Pediatr Res1988;23:408A.
33.
Goddard-Finegold J., Donley D., Adham BI, Michael LH: Phenobarbital and cerebral blood flow during hypertension in the newborn beagle. Pediatrics1990;86:501-508.
34.
Owens WC, Owens EU: Retrolental fibroplasia in premature infants. II. Studies on the prophylaxis of the disease. The use of alpha-tocopherol acetate. Am J Ophthalmol1949; 32:1631-1637.
35.
Hittner HM, Godio LB, Rudolph AJ, et al: Retrolental fibroplasia: Efficacy of vitamin E in a double-blind clinical study of preterm infants. N Engl J Med1981;305:1365-1371.
36.
Finer NN, Schindler RF, Grant G., et al: Effect of intramuscular vitamin E on frequency and severity of retrolental fibroplasia. Lancet1982;1:1087-1091.
37.
Puklin JE, Simon RM, Ehrenkranz RA: Influence on retrolental fibroplasia of intramuscular vitamin E administration during respiratory distress syndrome. Ophthalmology1982;89: 96-103.
38.
Schaffer DB , Johnson L., Quinn GE, et al: Vitamin E and retinopathy of prematurity. Follow-up at one year. Ophthalmology1985;92:1005-1011.
39.
Watts JL, Milner RA, McCormick AQ: Failure of vitamin E to prevent RLF. Clin Invest Med1985;8:A176.
40.
Law MR, Wijewardene K., Wald NJ: Is routine vitamin E administration justified in very low-birthweight infants?Dev Med Child Neurol1990;32:442-450.
41.
Keeler RF, Young S.: Role of vitamin E in the etiology of spontaneous hemorrhagic necrosis of the central nervous system of fetal hamsters. Teratology1979;20:127-132.
42.
Pappenheimer AM, Goettsch M.: A cerebellar disorder in chicks apparently of nutritional origin. J Exp Med1931;53:11-26.
43.
Phelps DL, Rosenbaum AL, Leake RD: Safety of intravascular tocopherol in a randomized double blind trial in premature infants. Pediatr Res1984;18:158A.
44.
Hittner HM, Speer ME, Rudolph AJ, et al: Retrolental fibroplasia and vitamin E in the preterm infant—comparison of oral versus intramuscular: Oral administration. Pediatrics1984; 73:238-249.
45.
Chiswick ML , Johnson M., Woodall C.: Protective effect of vitamin E (DL-alpha-tocopherol) against intraventricular hemorrhage in premature babies. BMJ1983;287:81-84.
46.
Sinha S., Davies J., Toner N., et al: Vitamin E supplementation reduces frequency of periventricular haemorrhage in very preterm babies. Lancet1987;1:466-470.
47.
Chiswick M. , Gladman G., Sinha S., et al: Vitamin E supplementation and periventricular hemorrhage in the newborn. Am J Clin Nutr1991;53(Suppl):370S-372S.
48.
Johnson L., Bowen FW, Abbasi S., et al: Relationship of prolonged pharmacologic serum levels of vitamin E to incidence of sepsis and necrotizing enterocolitis in infants with birth weight 1500 grams or less. Pediatrics1985 ;75:619-638.
49.
Ment LR, Stewart WB, Scott DT, et al: Beagle puppy model of intraventricular hemorrhage: Randomized indomethacin prevention trial. Neurology1983 ;33:179-184.
50.
Hanigan WC, Kennedy G., Roemisch F., et al: Administration of indomethacin for the prevention of periventricular/intraventricular hemorrhage in high-risk neonates. J Pediatr1988;112:941-947.
51.
Ment LR, Duncan CC, Ehrenkranz RA, et al: Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates. J Pediatr1988;112:948-955.
52.
Bandstra ES , Montalvo BM, Goldberg RN, et al: Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants . Pediatrics1988;82:533-542.
53.
Bada HS, Green RS, Pourcyrous M., et al: Indomethacin reduces the risks of severe intraventricular hemorrhage . J Pediatr1989;115:631-637.
54.
Hanigan W., Kennedy G., Roemisch F.: Prophylactic indomethacin for the prevention of periventricular/intraventricular hemorrhage, abstract. Pediatr Res1987;21:491A.
55.
Green RS, Bada HS, Leffler CW: Controlled trial of indomethacin (IND) prevention of neonatal intraventricular/ periventricular hemorrhage (IVH/PVH), abstract. Pediatr Res1987;21:362A.
56.
Rennie JM, Doyle J., Cooke RW: Early administration of indomethacin to preterm infants. Arch Dis Child1986;61: 223-238.
57.
Kovacs L., Falkay G.: Ethamsylate as inhibitor of prostaglandin biosynthesis in pregnant human myometrium in vitro. Experientia1981 ;37:1182-1183.
58.
Morgan ME, Benson JW, Cooke RW: Ethamsylate reduces the incidence of periventricular haemorrhage in very low birth weight babies. Lancet1981;2:830-831.
59.
Cooke RW, Morgan ME: Prophylactic ethamsylate for periventricular haemorrhage. Arch Dis Child1984;59:82-83.
60.
Benson JW, Drayton MR, Hayward C., et al: Multicentre trial of ethamsylate for prevention of periventricular haemorrhage in very low birth weight infants. Lancet1986;2: 1297-1300.
61.
Ment LR, Stewart WB, Duncan CC: Beagle puppy model of intraventricular hemorrhage: Ethamsylate studies . Prostaglandins1984;27:245-256.
62.
Rennie JM, Lom PK: Effect of ethamsylate on cerebral blood flow velocity in premature babies . Arch Dis Child1989;64:46-47.
63.
Pomerance JJ , Teal JG, Gogolok JF, et al: Maternally administered antenatal vitamin K1: Effect on neonatal prothrombin activity, partial thromboplastin time, and intraventricular hemorrhage . Obstet Gynecol1987;70:235-241.
64.
Morales WJ, Angel JL, O'Brien WF, et al: The use of antenatal vitamin K in the prevention of early neonatal intraventricular hemorrhage. Am J Obstet Gynecol1988;159:774-779.
65.
McCall T. , Vallance P.: Nitric oxide takes centre-stage with newly defined roles. Trends Pharmacol Sci1992;13:1-6.
66.
Gluckman P., Klempt N., Guan J., et al: A role for IGF-1 in the rescue of CNS neurons following hypoxic-ischemic injury. Biochem Biophys Res Commun1992;182:593-599.
67.
Adair J., Filloux F.: Effects of hypoxic-ischemic brain damage on dopaminergic markers in the neonatal rat: A regional autoradiographic analysis. J Child Neurol1992;7:199-207.
68.
Greenwald RA : Therapeutic benefits of oxygen radical scavenger treatments remain unproven. Free Radic Biol Med1985;1:173-177.
69.
Greenwald RA : Superoxide dismutase and catalase as therapeutic agents for human disease. Free Radic Biol Med1990;8:201-209.
70.
Flohe L.: Superoxide dismutase for therapeutic use: Clinical experience, dead ends, and hopes. Mol Cell Biochem1988;84:123-131.
71.
Ikeda Y., Long DM: The molecular basis of brain injury and brain edema: The role of oxygen free radicals. Neurosurgery1990;27:1-11.
72.
DiGiacomo JE , Pane CR, Gwiazdowski S., et al: Effect of graded hypoxia on brain cell membrane injury in newborn piglets. Biol Neonate1992;61:25-32.
73.
Goplerud JM , Mishra OP, Delivoria-Papadopoulos M.: Brain cell membrane dysfunction following acute asphyxia in newborn piglets. Biol Neonate1992;61:33-41.
74.
Granger DN: Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am J Physiol1988;255: H1269-H1275.
75.
Liu TH, Beckman JS, Freeman BA, et al: Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am J Physiol1989;256: H589- H593.
76.
Armstead WM , Mirro R., Thelin OP, et al: Polyethylene glycol superoxide dismutase and catalase attenuate increased blood-brain barrier permeability after ischemia in piglets. Stroke1992;23:755-762.
77.
Ment LR, Stewart WB, Duncan CC: Beagle puppy model of intraventricular hemorrhage. Effect of superoxide dismutase on cerebral blood flow and prostaglandins. J Neurosurg1985;62:563-569.
78.
Uyama O., Matsuyama T., Michishita H., et al: Protective effects of human recombinant superoxide dismutase in transient ischemic injury on CA1 neurons in gerbils. Stroke1992;23:75-81.
79.
Hall ED, Braughler JM, Yonkers PA, et al: U-78517F: A potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia. J Pharmacol Exp Ther1991;258:688-694.
80.
Young W., Wojak JC, DeCrescito V.: 21-Aminosteroid reduces ion shifts and edema in the rat middle cerebral artery occlusion model of regional ischemia. Stroke1988;19:1013-1019.
Iansek R., Packham D., Apsey BS, Harrison MJ: An assessment of the possible protective effect of allopurinol in acute stroke . Neurol Neurosurg Psychiatry1986;49:585-587.
83.
Martz D., Rayos G., Schielke GP, Betz AL: Allopurinol and dimethyliourea reduce brain infarction following middle cerebral artery occlusion in rats. Stroke1989;20:488-494.
84.
Mink RB, Dutka AJ, Hallenbeck JM: Allopurinol pretreatment improves evoked response recovery following global cerebral ischemia in dogs. Stroke1991 ;22:660-665.
85.
Lindsberg PJ , Hallenbeck JM, Feuerstein G.: Platelet-activating factor in stroke and brain injury. Ann Neurol1991;30:117-129.
86.
Kochanek PM , Nemoto EM, Melick JA, et al: Cerebrovascular and cerebrometabolic effects of intracarotid infused platelet activating factor in rats. J Cereb Blood Flow Metab1988;8:546-551.
87.
Karcher L., Zagermann P., Krieglstein J.: Effect of an extract of Gingko biloba on rat brain energy metabolism in hypoxia . Naunyn Schmiedebergs Arch Pharmacol1984 ;327:31-35.
88.
Oberpichler H., Sauer D., Rossberg C., et al: PAF antagonist gingkolide B reduces postischemic neuronal damage in rat brain hippocampus . J Cereb Blood Flow Metab1990;10: 133-135.
89.
Frerichs KU , Lindsberg PJ, Hallenbeck JM, et al: Platelet-activating factor and progressive brain damage following focal brain injury. J Neurosurg1990;73:223-233.
90.
Spinnewyn B. , Blavet N., Clostre F., et al: Involvement of platelet-activating factor (PAF) in cerebral post-ischemic phase in Mongolian gerbils. Prostaglandins1987;34:337-349.
91.
Kochanek PM , Dutka AJ, Kumaroo KK, et al: Platelet activating factor receptor blockade enhances recovery after multifocal brain ischemia . Life Sci1987;41:2639-2644.
92.
Panetta T., Marcheselli VL, Braquet P., et al: Effects of platelet activating factor antagonist (BN 52021) on free fatty acids, diacylglycerols, polyphosphoinositides, and blood flow in the gerbil brain: Inhibition of ischemia-reperfusion induced cerebral injury . Biochem Biophys Res Commun1987;149:580-587.
93.
Choi DW: Calcium-mediated neurotoxicity: Relationship to specific channel types and role in ischemic damage. Trends Neurosci1988 ;11:465-469.
Albers, GW, Goldberg MP, Choi DW: N-Methyl-D-aspartate antagonists: Ready for clinical trial in brain ischemia?Ann Neurol1989;25:398-403.
96.
Johnston MV: Physiological and pathophysiological roles of excitatory amino acids during central nervous system development, in Fukuyama Y, Suzuki Y, Kamoshita S, Casaer P (eds): Fetal and Perinatal Neurology. Basel, Karger, 1992, pp 19-30.
97.
George CP, Goldberg MP, Choi DW, Steinberg GK: Dextromethorphan reduces neocortical ischemic neuronal damage in vivo . Brain Res1988;440:375-379.
98.
Steinberg GK , George CP, DeLaPaz RL, et al: Dextromethorphan protects against cerebral injury following transient focal ischemia in rabbits . Stroke1988;19:1112-1118.
99.
Prince DA, Feeser HR: Dextromethorphan protects against cerebral infarction in a rat model of hypoxia-ischemia . Neurosci Lett1988;85:291-296.
100.
Tortella FC , Martin DA, Allot CP, et al: Dextromethorphan attenuates post-ischemic hypoperfusion following incomplete global ischemia in the anesthetized rat . Brain Res1989;482:179-183.
101.
Goldberg MP , Pham P-C., Choi DK: Dextrorphan and dextromethorphan attenuate hypoxic injury in neuronal culture. Neurosci Lett1987;80:11-15.
102.
Steinberg GK , Saleh J., DeLaPaz R., et al: Pretreatment with the NMDA antagonist dextrorphan reduces cerebral injury following transient focal ischemia in rabbits. Brain Res1989;497:382-386.
103.
Steinberg GK , Saleh J., DeLaPaz R., et al: Postischemic treatment with the NMDA antagonist dextrorphan protects against cerebral injury after focal ischemia: A dose-dependent response . J Cereb Blood Flow Metab1989;9(Suppl 1):S283.
104.
Kent TA, Eisenberg H., Quast M., et al: Dextrorphan reduces infarct volume after middle cerebral occlusion in rats: A magnetic resonance imaging and histopathology study. J Cereb Blood Flow Metab1989;9(Suppl):S153.
105.
Swan JH, Meldrum BS: Protection by NMDA antagonists against selective cell loss following transient ischaemia. J Cereb Blood Flow Metab1990;10:343-351.
106.
Lysko PG, Gagnon RC, Yue TL, et al: Neuroprotective effects of SKF 10,047 in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke1992;23:414-419.
107.
Gill R., Foster AC, Woodruff GN: Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J Neurosci1987;7:3343-3349.
108.
Kochar A., Zivin JA, Lyden PD, et al: Glutamate antagonist therapy reduces neurologic deficit produced by focal central nervous system ischemia. Arch Neurol1988;45:148-153.
109.
Ozyurt E., Graham DI, Woodruff GN, et al: Protective effect of the glutamate antagonist MK-801 in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab1988;8:138-143.
110.
Gill R., Foster AC, Woodruff GN: MK-801 is neuroprotective in gerbils when administered during the post-ischaemic period. Neuroscience1988;25:847-855.
111.
Church J., Zeman S., Lodge D.: The neuroprotective action of ketamine and MK-801 after transient cerebral ischemia in rats. Anesthesiology1988;69:702-709.
112.
Park CK, Nehls DG, Graham DI, et al: The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol1988;24:543-551.
113.
Park CK, Nehls DG, Graham DI, et al: Focal cerebral ischemia in the cat: Treatment with the glutamate antagonist MK-801 after induction of ischemia. J Cereb Blood Flow Metab1988;8:757-762.
114.
Rod MR , Auer RN: Pre- and post-ischemic administration of dizocilpine (MK-801) reduces cerebral necrosis in the rat. Can J Neurol Sci1989;16:340-344.
115.
Dalkara T. , Tan E., Erdemli G., et al: Electrophysiological evidence for activation of NMDA receptors and its antagonism by MK-801 in cerebral ischemia . Brain Res1990;532:101-106.
116.
Pohorecki R., Becker GL, Reilly PJ, et al: Ischemic brain injury in vitro: Protective effects of NMDA receptor antagonists and calmidazolium . Brain Res1990;528:133-137.
117.
Priestley T., Horne AL, McKernan RM, et al: The effect of NMDA receptor glycine site antagonists on hypoxia-induced neurodegeneration of rat cortical cell cultures. Brain Res1990 ;531:183-188.
118.
Gill R., Kemp JA: Protection of CA1 pyramidal cell function by MK-801 following ischaemia in the gerbil. Neurosci Lett1989;105:101-106.
119.
Boxer PA, Cordon JJ, Mann ME, et al: Comparison of phenytoin with noncompetitive N-methyl-D-aspartate antagonists in a model of focal brain ischemia in rat. Stroke1990; 21(Suppl):11147-11151.
120.
Hattori H. , Wasterlain CG: Hypothermia does not explain MK-801 neuroprotection in a rat model of neonatal hypoxic-ischemic encephalopathy . Neurology1991;41:330.
121.
Ikonomidou C., Mosinger JL, Shahid Salles K, et al: Sensitivity of the developing rat brain to hypobaric/ischemic damage sensitivity to NMDA neurotoxicity. J Neurosci1989;9: 2809-2818.
122.
McDonald JW , Silverstein FS, Johnston MV: MK-801 protects the neonatal brain from hypoxic-ischemic damage. Eur J Pharmacol1987;140:359-361.
123.
Ford LM, Sanberg PR, Norman AB, Fogelson MH: MK-801 prevents hippocampal neurodegeneration in neonatal hypoxic-ischemic rats. Arch Neurol1989;46:1090-1096.
124.
Hattori H. , Morin AM, Schwartz PH, et al: Posthypoxic treatment with MK-801 reduces hypoxic-ischemic damage in the neonatal rat . Neurology1989;39:713-718.
125.
Olney JW, Ikonomidou C., Mosinger JL, et al: MK-801 prevents hypobaric-ischemic neuronal degeneration in infant rat brain. J Neurosci1989;9:1701-1704.
126.
Speiser Z. , Uziel J., Defrin-Assa R., et al: Different behavioral deficits are induced by anoxia/hypoxia in neonatal and senescent rats: Blockade by MK-801 . Behav Brain Res1991;42:181-186.
127.
Nozaki K., Beal MF: Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J Cereb Blood Flow Metab1992;12:400-407.
128.
Kostron H. , Sperl W., Murr C., Pillwein K.: Effect of the calcium entry blocker nimodipine on the metabolism of nucleic acids in rat brain ischemia. Adv Neurol1990;52:133-139.
129.
Hakim AM, Evans AC, Berger L., et al: The effect of nimodipine on the evolution of human cerebral infarction studied by PET. J Cereb Blood Flow Metab1989;9:523-534.
130.
Hara H., Onodera H., Nagasawa H., Kogure K.: Effect of nimodipine on ischemia-induced brain edema and mortality in a novel transient middle cerebral artery occlusion model. Jpn J Pharmacol1990;53:247-253.
131.
Jacewicz M. , Brint S., Tanabe J., Pulsinelli WA: Continuous nimodipine treatment attenuates cortical infarction in rats subjected to 24 hours of focal cerebral ischemia . J Cereb Blood Flow Metab1990;10:89-96.
132.
Jacewicz M. , Brint S., Tanabe J., et al: Nimodipine pretreatment improves cerebral blood flow and reduces brain edema in conscious rats subjected to focal cerebral ischemia. J Cereb Blood Flow Metab1990;10:903-913.
133.
Bielenberg GW, Burniol M., Rosen R., Klaus W.: Effects of nimodipine on infarct size and cerebral acidosis after middle cerebral artery occlusion in the rat. Stroke1990;21(Suppl): IV90-IV92.
134.
Teasdale G. , Mendelow AD, Graham DI, et al: Efficacy of nimodipine in cerebral ischemia or hemorrhage. Stroke1990;21(Suppl):IV123-IV125.
135.
Hara H., Nagasawa H., Kogure K.: Nimodipine prevents postischemic brain damage in the early phase of focal cerebral ischemia. Stroke1990;21(Suppl):IV102-IV104.
136.
Lazarewicz JW, Pluta R., Puka M., et al: Diverse mechanisms of neuronal protection by nimodipine in experimental rabbit brain ischemia . Stroke1990;21(Suppl):IV108-IV110.
137.
Welsch M., Nuglisch J., Krieglstein J.: Neuroprotective effect of nimodipine is not mediated by increased cerebral blood flow after transient forebrain ischemia in rats. Stroke1990;21(Suppl):IV105-IV107.
138.
Mossakowski MJ, Gadamski R.: Nimodipine prevents delayed neuronal death of sector CA1 pyramidal cells in shortterm forebrain ischemia in Mongolian gerbils. Stroke1990;21(Suppl):IV120-IV122.
139.
Gotti B., Benavides J., MacKenzie ET, Scatton B.: The pharmacotherapy of focal cortical ischemia in the mouse. Brain Res1990;522:290-307.
140.
Alps BJ, Calder C., Hass WK, Wilson AD: Comparative protective effects of nicardipine, flunarizine, lidoflazine and nimodipine against ischaemic injury in the hippocampus of the Mongolian gerbil . Br J Pharmacol1988;93:877-883.
141.
Tateishi A., Fleischer JE, Drummond JC, et al: Nimodipine does not improve neurologic outcome after 14 minutes of cardiac arrest in cats. Stroke1989;20:1044-1050.
142.
Vibulsreth S., Dietrich WD, Busto R., Ginsberg MD: Failure of nimodipine to prevent ischemic neuronal damage in rats. Stroke1987;18:210-216.
143.
Lazarewicz JW, Pluta R., Salinska E., et al: Beneficial effect of nimodipine on metabolic and functional disturbances in rabbit hippocampus following complete cerebral ischemia. Stroke1989;20:70-77.
144.
Paci A., Ottaviano P., Trenta A., et al: Nimodipine in acute ischemic stroke: A double-blind controlled study. Acta Neurol Scand1989;80:282-286.
145.
Gelmers HJ , Gorer K., de Weerdt CJ , Wiezer HJ: A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med1988;318:203-207.
146.
Roine RO, Kaste M., Kinnunen A., et al: Nimodipine after resuscitation from out-of-hospital ventricular fibrillation. A placebo-controlled, double-blind, randomized trial. JAMA1990;264:3171- 3177.
147.
Gelmers HJ , Hennerici M.: Effect of nimodipine on acute ischemic stroke. Pooled results from five randomized trials. Stroke1990;21(Suppl):IV81-IV84.
148.
Sauter A., Rudin M.: Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging . Stroke1986;17:1228-1234.
149.
Sauter A., Rudin M., Wiederhold KH, Hof RP: Cerebrovascular, biochemical, and cytoprotective effects of isradipine in laboratory animals. Am J Med1989;86:134-146.
150.
Sauter A., Rudin M., Wiederhold KH: Reduction of neural damage in irreversible cerebral ischemia by calcium antagonists . Neurochem Pathol1988;9:211-236.
151.
Yoshidomi M., Hayashi T., Abe K., Kogure K.: Effects of a new calcium channel blocker, KB-2796, on protein synthesis of the CA1 pyramidal cell and delayed neuronal death following transient forebrain ischemia. J Neurochem1989;53: 1589-1594.
152.
Sakabe T.: Calcium entry blockers in cerebral resuscitation. Magnesium1989;8:238-252.
153.
Nikolov R. , Nikolova M., Dikova M., et al: Cerebroprotective effect of flunarizine . Methods Find Exp Clin Pharmacol1990;12:411-418.
154.
Kawamura S. , Shirasawa M., Fukasawa H., Yasui N.: Attenuated neuropathology by nilvadipine after middle cerebral artery occlusion in rats. Stroke1991;22:51-55.
155.
Kuwaki T., Satoh H., Ono T., et al: Nilvadipine attenuated ischemic degradation of gerbil brain cytoskeletal proteins. Stroke1989;20:78-83.
156.
Mogilner M. , Ashwal S., Dale PS, Longo LD: Effect of nimodipine on newborn lamb blood flow. Biol Neonate1988 ;53:279-289.
157.
Hakim AM, Evans AC, Berger L., et al: The effect of nimodipine on the evolution of human cerebral infarction studied by PET. J Cereb Blood Flow Metab1989;9:523-534.
158.
Pozzilli C. , Di Piero V., Pantano P., et al: Influence of nimodipine on cerebral blood flow in human cerebral ischaemia. J Neurol1989;236:199-202.
159.
Young WL, Josovitz K., Morales O., Chien S.: The effect of nimodipine on post-ischemic cerebral glucose utilization and blood flow in the rat. Anesthesiology1987 ;67:54-59.
160.
Nuglisch J. , Karkoutly C., Mennel HD, et al: Protective effect of nimodipine against ischemic neuronal damage in rat hippocampus without changing postischemic cerebral blood flow. J Cereb Blood Flow Metab1990;10:654-659.
161.
Sutherland G., Lesiuk H., Bose R., et al: Effect of mannitol, nimodipine, and indomethacin singly or in combination on cerebral ischemia in rats. Stroke1988;19:571-578.
162.
Little JR: Treatment of acute focal cerebral ischemia with intermittent, low dose mannitol . Neurosurgery1979;5:687-691.
163.
Little JR: Modification of acute focal ischemia by treatment with mannitol. Stroke1978;9:4-9.
164.
Adhikari M. , Moodley M., Desai PK: Mannitol in neonatal cerebral oedema. Brain Dev1990;12:349-351.
165.
Bielenberg GW, Burkhardt M.: 5-Hydroxytryptamine1A agonists: A new therapeutic principle for stroke treatment. Stroke1990 ;21(Suppl):IV161-IV163.
166.
Wagener G. , Hielscher H., Rossberg C., et al: Effects of ipsapirone on spatial and temporal changes in somatosensory evoked potentials after middle cerebral artery occlusion in the rat. Stroke1990;21(Suppl):IV167-IV170.
167.
Bode-Greuel KM, Klisch J., Horvath E., et al: Effects of 5-hydroxytryptaminel1A-receptor agonists on hippocampal damage after transient forebrain ischemia in the Mongolian gerbil. Stroke1990;21(Suppl):IV164-IV166.
